Clinical trials: Clinical High Risk for Psychosis
Clinical High Risk for Psychosis (CHR)
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks.
- Trial name
- NCT07226895
- Testing
- MT1988 Low Dose, MT1988 High Dose
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- Monument Therapeutics Limited